Charles River Laboratories International (CRL) News
Market Cap: $5.63B
Avg Volume: 1.68M
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Ahead of AACR 2025, Charles River announces updates to its comprehensive portfolio to support the discovery and development of novel oncology drugs.
businesswire.com
Read More
Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity
Aldeyra Therapeutics' stock offers a compelling contrarian opportunity, rebounding 70% after a 75% drop due to an FDA CRL for Reproxalap in dry eye disease. The FDA requested additional efficacy data. Aldeyra already has two trials with data expected in Q2 2025, aiming for NDA resubmission by mid-2025. Reproxalap targets upstream inflammation, offering rapid symptom relief in a large market, with a risk-adjusted U.S. revenue potential of $216 million annually.
seekingalpha.com
Read More
The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?
It's been a turbulent start to 2025 for investors. The market has faced a wave of selling pressure driven by surging tariffs, escalating geopolitical tensions, and growing fears of a global economic slowdown.
marketbeat.com
Read More
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules first-quarter 2025 earnings release and conference call.
businesswire.com
Read More
Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?
Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
zacks.com
Read More
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
benzinga.com
Read More
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com
Read More
After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy
Aldeyra Therapeutics' stock plummeted 74% due to an FDA Complete Response Letter for reproxalap but presents a favorable risk-reward for speculative investors. Despite past setbacks, ALDX's history of resilience and upcoming trial results offer potential catalysts for recovery, with minimal near-term dilution risk. ALDX's strong cash position and reduced burn rate provide a safety net, with significant upside potential if reproxalap trials succeed and FDA approval is achieved.
seekingalpha.com
Read More
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate
Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.
zacks.com
Read More
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform
WILMINGTON, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Valo Health announce the identification of an advanceable product candidate for treatment of lupus and other autoimmune diseases.
businesswire.com
Read More
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
zacks.com
Read More
FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility
PORTO, Portugal & SAN FRANCISCO--(BUSINESS WIRE)--FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced that it had completed the acquisition of the South San Francisco site from Charles River Laboratories International, Inc. The acquisition aligns with FairJourney's ongoing strategic growth plan, and will significantly bolster the Company's antibody discovery and engineering capabilities, strengthening its technology portfolio and expanding its gl.
businesswire.com
Read More
Deciphering Charles River (CRL) International Revenue Trends
Examine the evolution of Charles River's (CRL) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
zacks.com
Read More
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance
On Wednesday, Charles River Laboratories International Inc CRL reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1% year over year, beating the consensus of $983.63 million.
benzinga.com
Read More
Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL ) Q4 2024 Earnings Call February 19, 2025 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Dave Windley - Jefferies Ann Hynes - Mizuho Justin Bowers - Deutsche Bank Lucas Romanski - TD Cowen Michael Ryskin - Bank of America Max Smock - William Blair Jacob Johnson - Stephens Patrick Donnelly - Citi Casey Woodring - JPMorgan Operator Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded.
seekingalpha.com
Read More
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall
Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.
zacks.com
Read More
Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Read More
Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.50 per share. This compares to earnings of $2.46 per share a year ago.
zacks.com
Read More
Charles River beats quarterly estimates on stable demand for drug development services
Charles River Laboratories on Wednesday beat fourth-quarter profit and revenue estimates, helped by stable demand for its drug discovery and development services from biotech clients.
reuters.com
Read More
Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
zacks.com
Read More
Is Now the Right Time to Hold on to Charles River Stock?
CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.
zacks.com
Read More
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Read More
Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions
WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex focus on advancing image management solutions, while developing novel AI tools for toxicologic pathology.
businesswire.com
Read More
CRL Gears Up for Q4 Earnings: Here's What You Need to Know
Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.
zacks.com
Read More
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
CRL introduces Apollo for CRADL, integrating the technology stack across its robust portfolio.
zacks.com
Read More
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River expands Apollo ecosystem, offering bespoke client experiences that enable data-driven decision making.
businesswire.com
Read More
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line?
Charles River and Akron Bio collaborate to boost operations by integrating CGMP materials into the Cell Therapy Platform.
zacks.com
Read More
Should You Retain Charles River Stock in Your Portfolio Now?
CRL's solid prospects in the RMS segment and solid financial stability create a favorable outlook for investors.
zacks.com
Read More
Why Is Charles River (CRL) Down 8.9% Since Last Earnings Report?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
zacks.com
Read More
CRL Stock to Gain From the Global Biotech Incubator Program Launch
Charles River's new initiative specifically caters to early-stage biotechnology developers.
zacks.com
Read More
Charles River Introduces Global Biotech Incubator Program
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing in supporting early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies. “The Charles River Incubator Program launch, through our Global Innovation Center of Excellence, demonstrates a continued commitment to the global biotechnology industry by offeri.
businesswire.com
Read More
Is it the Right Time to Hold Charles River Stock in Your Portfolio?
Investors are optimistic about CRL stock due to its strong RMS prospects and inorganic growth efforts.
zacks.com
Read More
Charles River (CRL) International Revenue in Focus: Trends and Expectations
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
zacks.com
Read More
Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL ) Q3 2024 Earnings Conference Call November 6, 2024 9:30 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foster - President and Chief Executive Officer Flavia Pease - Chief Financial Officer Conference Call Participants Max Smock - William Blair & Company Matthew Sykes - Goldman Sachs David Windley - Jefferies Group LLC Eric Coldwell - Robert W. Baird & Co. Justin Bowers - Deutsche Bank Dan Leonard - UBS Group AG Elizabeth Anderson - Evercore ISI Michael Ryskin - BofA Securities, Inc. Tejas Savant - Morgan Stanley Casey Woodring - JPMorgan Chase & Co. Luke Sergott - Barclays Patrick Donnelly - Citigroup Inc. Operator Please stand by, we're about to begin.
seekingalpha.com
Read More
Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall
CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment.
zacks.com
Read More
Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Read More
Charles River Laboratories (CRL) Q3 Earnings and Revenues Beat Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.72 per share a year ago.
zacks.com
Read More
Charles River Laboratories raises annual profit forecast on stabilizing biotech demand
Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients for its drug discovery and development services.
reuters.com
Read More
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Read More
Why Charles River (CRL) is Poised to Beat Earnings Estimates Again
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com
Read More
CRL Gears Up for Q3 Earnings: Here's What You Need to Know
Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand.
zacks.com
Read More
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch
Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.
zacks.com
Read More
Charles River Launches New Retrogenix® Non-Human Protein Library
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Retrogenix® Non-Human Protein Library to support assessment of off-target binding, de-risk studies & aid model selection.
businesswire.com
Read More
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules third-quarter 2024 earnings release and conference call.
businesswire.com
Read More
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs.
zacks.com
Read More
Operadora de Fondos Banorte Adopts Charles River's Cloud-Based Platform
BOSTON--(BUSINESS WIRE)--Banorte is now live on Charles River's cloud-based Investment Management Solution.
businesswire.com
Read More
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA
Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.
zacks.com
Read More
Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing
New Biological Data Released from IRO® Cell Therapy Manufacturing Platform New Biological Data Released from IRO® Cell Therapy Manufacturing Platform
globenewswire.com
Read More
CRL Stock May Benefit From New Neuroscience Research Collaboration
Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.
zacks.com
Read More
Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
zacks.com
Read More
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties
SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to CRL and its shareholders.
globenewswire.com
Read More
Charles River Laboratories: Changing Economics Reduces Compounding Ability (Rating Downgrade)
Charles River came in with another set of soft numbers, indicating a period of weaker business ahead for the company. Management is scaling back CapEx into the business and focusing on buybacks, suggesting there's no viable reinvestment opportunities to grow. The intrinsic worth of the business is $215–$223/share under present conditions, in my opinion, warranting a hold.
seekingalpha.com
Read More
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Charles River Laboratories International, Inc. (NYSE: CRL) on behalf of long-term stockholders following a class action complaint that was filed against Charles River on May 19, 2023 with a Class Period from May 5, 2020 to February 21, 2023. Our investigation concerns whether the board of directors of Charles River have breached their fiduciary duties to the company.
globenewswire.com
Read More
Why Charles River (CRL) International Revenue Trends Deserve Your Attention
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
zacks.com
Read More
Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Weak biopharma market challenges persist, impacting CRL's revenue and bottom-line growth. Cost streamlining initiatives in place to generate $150 million in annualized cost savings by FY25. Growth projection includes a 3% revenue decline in FY24, with a fair value of $220 per share based on DCF analysis.
seekingalpha.com
Read More
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.
zacks.com
Read More
Charles River Laboratories International Inc (CRL) Q2 2024 Earnings Call Transcript
Charles River Laboratories International Inc (NYSE:CRL ) Q2 2024 Results Conference Call August 7, 2024 9:00 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relations Jim Foster - CEO, President & Chairman Flavia Pease - Corporate Executive VP & CFO Conference Call Participants Matt Sykes - Goldman Sachs Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Dave Windley - Jefferies Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Casey Woodring - JPMorgan Luke Sergott - Barclays Michael Ryskin - Bank of America Max Smock - William Blair Operator Ladies and gentlemen, thank you for standing by, and welcome to Charles River Laboratories Second Quarter 2024 Earnings Conference Call. Just a reminder, this call is being recorded.
seekingalpha.com
Read More
Charles River Labs Says It Expects Sales To Fall, Sending Its Stock Tumbling
Shares of Charles River Laboratories (CRL) tumbled over 12% in intraday trading Wednesday after the company said it expects to post a decline in sales for the full fiscal year, instead of growth.
investopedia.com
Read More
Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Read More
Charles River Laboratories Stock Sinks As It Warns Of Continued Biotech Demand Slump, Lowers Forecast
Charles River Laboratories International Inc CRL reported second-quarter 2024 revenue of $1.03 billion on Wednesday, a decrease of 3.2% year over year, beating the consensus of $1.024 billion.
benzinga.com
Read More
Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.69 per share a year ago.
zacks.com
Read More
Charles River cuts 2024 forecast as funding crunch among biotech clients persists
Charles River Laboratories trimmed its annual forecast on Thursday, as it no longer expects demand for its drug discovery and development services to improve in the second half of the year, sending its shares down 15% in premarket trading.
reuters.com
Read More
Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
zacks.com
Read More
Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings
Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.
zacks.com
Read More
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules second-quarter 2024 earnings release and conference call for Wednesday, August 7th.
businesswire.com
Read More
Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy
Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.
zacks.com
Read More
Charles River to Perform Plasmid Manufacturing for AAVantgarde
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good Manufacturing Practice- (GMP) plasmid DNA. AAVantgarde, a clinical-stage biotechnology company with two proprietary adeno-associated viral (AAV) vector platforms for large gene delivery and developing products to treat inherited retinal diseases, will leverage Charles River's expertis.
businesswire.com
Read More
Charles River (CRL) Could be an Apt Pick Right Now: Here's Why
Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.
zacks.com
Read More
Charles River's (CRL) RMS Growth Aids Amid FX Headwind
Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.
zacks.com
Read More
Charles River (CRL) Inks CDMO Deal With Gates Institutes
Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.
zacks.com
Read More
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
ROCKVILLE, Md.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River's premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell.
businesswire.com
Read More
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.
zacks.com
Read More
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River's Cell and Gene Therapy (CGT) Accelerator Program (CAP), Captain T Cell will have access to established plasmid and viral vector contract development and manufacturing organization (CDMO) capabilities and advisor.
businesswire.com
Read More
Charles River (CRL) Partners to Reduce Animal Research Usage
Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.
zacks.com
Read More
Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces an integrated program, funded by a $1.3 million grant, to develop an in vitro alternative to inhalation toxicology studies.
businesswire.com
Read More
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the opening of a new CRADL® facility on Chestnut Street in Somerville, Massachusetts, an emerging life sciences hub.
businesswire.com
Read More
Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the launch of its Virtual Control Groups (VCG) initiative with Sanofi to reduce the use of animals in research.
businesswire.com
Read More
Charles River Laboratories to Present at William Blair and Jefferies Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4th, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:00 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be avai.
businesswire.com
Read More
Charles River (CRL) Launches Viral Vector Tech Transfer Program
Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.
zacks.com
Read More
Charles River Laboratories: Fair Valuation Against Fundamentals
The life sciences tools and services industry is projected to grow at the rate of 10.8% per year into 2030, driven by advancements in gene sequencing, chromatography, and AI. Charles River Laboratories is a promising investment in this industry, with consistent earnings growth and strong free cash flow margins. CRL's steady Q1 performance and positive outlook for 2024 indicate potential for growth, particularly in its manufacturing solutions division.
seekingalpha.com
Read More
Reasons to Hold Charles River (CRL) in Your Portfolio Now
Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.
zacks.com
Read More
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track viral vector technology (tech) transfer frameworks. Based on decades of viral vector contract development and manufacturing organization (CDMO) experience, the Company has designed a methodical program to drive successful, accelerated process transfer to its Maryland-based viral vector center of excellence (CoE) in as little as nine months.
businesswire.com
Read More
Titian Receives Multi-Year Commitment from Charles River for Mosaic Sample Management Software
LONDON--(BUSINESS WIRE)-- #lifesciences--Titian Software and Charles River Laboratories have entered into a new 3-year partnership agreement, expanding Charles River's sample management capabilities. Titian's Mosaic sample management software is already well-established within Charles River's Discovery division, where the company has used the platform for 12 years to support programs from hit-identification to candidate selection. This agreement aims to add significant new capabilities to Charles River's sampl.
businesswire.com
Read More
Charles River (CRL) Banks on RMS Growth Amid Competition
Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.
zacks.com
Read More
Don't Overlook Charles River (CRL) International Revenue Trends While Assessing the Stock
Explore Charles River's (CRL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
zacks.com
Read More
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
Read More
Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y
Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.
zacks.com
Read More
Charles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Read More
The 7 Best Growth Stocks to Buy in May 2024
It's been a tremendous year for growth stocks. New technologies and increasing consumer adoption in fields such a semiconductors, electric vehicles, and generative AI have led to tremendous gains for growth stocks.
investorplace.com
Read More
Charles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
zacks.com
Read More
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality. Moving towards a gold standard for reference materials, Charles River is introducing six AAV reference material serotypes, offering superior e.
businesswire.com
Read More
ICLR vs. CRL: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Icon PLC (ICLR) and Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
zacks.com
Read More
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.
zacks.com
Read More
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--In addition to advancing human health and improving quality of life, we are dedicated to a responsible tomorrow.
businesswire.com
Read More
Here's Why You Should Retain Charles River (CRL) Stock Now
Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.
zacks.com
Read More
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Alternative Methods Advancement Project (AMAP), an initiative to develop alternatives to reduce animal testing.
businesswire.com
Read More